Faculty of Medicine, Pathology, Menoufia University, Shebin El-Kom, Egypt.
Menoufia University National Liver Institute, Pathology, Shebin El-Kom, Egypt.
J Immunoassay Immunochem. 2022 Jul 4;43(4):420-434. doi: 10.1080/15321819.2022.2034646. Epub 2022 Feb 13.
Hepatocellular carcinoma (HCC) is the most prevalent primary cancer of the liver and it is the fourth most common cause of cancer related death worldwide. In Egypt, liver cancer constitutes the most common cause of mortality-related cancer. This study aimed to evaluate the immunohistochemical expression of SET oncoprotein in HCC tissues in comparison with its expression in non tumorous liver tissues and to correlate its expression with clinicopathological parameters. This study investigated 100 cases of HCC (including tumorous and non tumorous tissues). One hundred percent of tumorous and non-tumorous tissues were positive for SET expression. The mean and median values of -score for SET expression were higher in tumorous than non tumorous tissues ( = .03). Higher SET expression was significantly correlated with larger tumor size ( = .012), positive lymphovascular invasion ( = .028), and shorter overall survival ( < .001). SET expression in tumor tissues is the most independent factor to affect the overall survival of HCC patients. SET plays a role in hepatocarcinogenesis proved by the increase of SET expression from non-tumorous to tumorous tissues. Also, SET can be used as a prognostic indicator and a novel target therapy in HCC patients.
肝细胞癌 (HCC) 是最常见的原发性肝癌，也是全球第四大常见癌症死亡原因。在埃及，肝癌是与癌症相关死亡的最常见原因。本研究旨在评估 SET 癌蛋白在 HCC 组织中的免疫组织化学表达，并与非肿瘤性肝组织中的表达进行比较，并将其表达与临床病理参数相关联。本研究调查了 100 例 HCC（包括肿瘤性和非肿瘤性组织）。100%的肿瘤性和非肿瘤性组织均为 SET 表达阳性。SET 表达的平均和中位数评分值在肿瘤性组织中高于非肿瘤性组织（ = 0.03）。更高的 SET 表达与更大的肿瘤大小（ = 0.012）、阳性的淋巴血管侵犯（ = 0.028）和更短的总生存期（< 0.001）显著相关。肿瘤组织中 SET 的表达是影响 HCC 患者总体生存的最独立因素。SET 在肝癌发生中的作用已得到证实，即 SET 表达从非肿瘤组织到肿瘤组织的增加。此外，SET 可作为 HCC 患者的预后指标和新的靶向治疗靶点。
